ZBIO · XBRL financial data
Zenas BioPharma financial statements, every fiscal year
The same tables from 2 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (ZBIO's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Revenue | 5,000 | 10,000 |
| Revenue from contracts with customers | 5,000 | 10,000 |
| Research and development | 139,139 | 168,063 |
| General and administrative | 29,749 | 53,322 |
| Total operating expenses | 168,888 | 393,057 |
| Operating income (loss) | (163,888) | (383,057) |
| Interest income | 7,973 | 12,151 |
| Interest expense | — | 7,327 |
| Other income (expense) | 8,175 | 417 |
| Income tax expense (benefit) | 429 | (79) |
| Net income (loss) | (156,988) | (377,737) |
| Earnings per share, basic USD per share | (11.89) | (8.44) |
| Earnings per share, diluted USD per share | (11.89) | (8.44) |
| Weighted average shares, basic thousands of shares | 13,199 | 44,730 |
| Weighted average shares, diluted thousands of shares | 13,199 | 44,730 |
Balance sheet
CSVFiscal years (ZBIO's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Cash and cash equivalents | 319,742 | 110,641 |
| Short-term investments | 31,024 | 232,551 |
| Marketable securities | 31,024 | 249,823 |
| Prepaid and other current assets | 5,067 | 7,979 |
| Total current assets | 355,923 | 351,171 |
| Property and equipment, net | 185 | 34 |
| Right-of-use asset | 1,004 | 1,354 |
| Total assets | 369,968 | 383,640 |
| Accounts payable | 17,136 | 7,111 |
| Accrued liabilities | 39,371 | 54,423 |
| Total current liabilities | 57,292 | 62,649 |
| Long-term debt | — | 78,636 |
| Lease liability, non-current | 218 | 211 |
| Total liabilities | 57,510 | 141,496 |
| Accumulated deficit | (387,391) | (765,128) |
| Total stockholders' equity | 312,458 | 242,144 |
| Total liabilities and equity | 369,968 | 383,640 |
| Common shares outstanding (cover page) thousands of shares | 41,799 | 57,361 |
Cash flows
CSVFiscal years (ZBIO's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Net income (loss) | (156,988) | (377,737) |
| Stock-based compensation | 10,821 | 26,347 |
| Net cash from operating activities | (119,674) | (172,333) |
| Purchases of property and equipment | 131 | 18 |
| Net cash from investing activities | (30,552) | (251,886) |
| Net cash from financing activities | 412,958 | 215,280 |
| Net change in cash | 262,889 | (209,191) |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Zenas BioPharma | 177,778 | 10,000 | (57,984)* | 67.8M | 9.2 quarters | 10-QSep 30, 2026 |
| Atea Pharmaceuticals | 76,548 | not reported | (37,084)* | 80.2M | 5.9 quarters | 10-QJun 30, 2026 |
| Verastem | 136,353 | 40,078 | (43,909)* | 90.6M | 3.1 quarters | 10-QJun 30, 2026 |
| Corvus Pharmaceuticals | 18,905 | not reported | (15,398)* | 84.1M | 14.0 quarters | 10-QJun 30, 2026 |
| DBV Technologies | 165,700 | 1,600 | (51,500)* | 314.4M | 3.2 quarters | 10-QSep 30, 2026 |
| Vanda Pharmaceuticals | 61,933 | 69,815 | (28,435)* | 60.5M | 1.7 quarters | 10-QSep 30, 2026 |
| Tonix Pharmaceuticals Holding | 176,232 | 13,544 | (42,243)* | 17.2M | 4.2 quarters | 10-QJun 30, 2026 |
| Abeona Therapeutics | 56,229 | 11,380 | (17,496)* | 57.2M | 8.4 quarters | 10-QJun 30, 2026 |
| Annexon | 199,270 | not reported | (48,007)* | not reported | 4.4 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.